IMAGE

Supplementary Figure 4.jpg (97.94 kB)

IMAGE

Supplementary Figure 5.jpg (109.55 kB)

IMAGE

Supplementary figure 6.jpg (144.38 kB)

IMAGE

Supplementary figure 7.jpg (100.53 kB)

IMAGE

Supplementary figure 2.jpg (140.03 kB)

IMAGE

Supplementary figure 3.jpg (197.87 kB)

DOCUMENT

Supplementary_data_file 02.docx (1.03 MB)

IMAGE

Supplementary figure 1.jpg (72.73 kB)

1/0

8 files

Preparation and characterization of amoxapine- and naringin-loaded solid lipid nanoparticles: drug-release and molecular-docking studies - supplementary dataset

dataset

posted on 2023-02-14, 11:59 authored by Sandeep Jat, Manini Bhatt, Sanjana Roychowdhury, Vaibhav A Dixit, Sachin Dattram Pawar, Hitesh Kulhari, Amit Alexander, Pramod Kumar

Aim: Amoxapine (AMX) has been reported to be metabolized by CYP3A4 and CYP2D6. Naringin (NG) has

been reported to inhibit CYP enzymes. Therefore, the current work was designed to develop AMX solid

lipid nanoparticles (AMX-SLNs) and NG-SLNs for better therapeutic performance. Materials & methods:

AMX-SLNs and NG-SLNs were prepared and characterized. AMX and NG interactions with CYP450s were studied with molecular docking to rationalize the effectiveness of the combination. Results: AMX-SLNs

and NG-SLNs showed nanometric size with a sustained in vitro drug-release profile. NG showed a higher

predicted binding affinity for CYP3A4 and CYP2D6, suggesting the potential for inhibition. Conclusion:

The developed formulations were thoroughly characterized along with molecular docking data indicating

promising AMX and NG combinations that may show good therapeutic activity.